JAK1 and neoplasm: Although inconclusive, numbers of ICI-resistant markers have been proposed for MSI-H tumours, including low TMB, Janus kinase (JAK1/2/3) mutations, loss of beta-2-microglobulin (B2M) that could impair antigen presentation by class I major histocompatibility complex [6, 20, 22, 23].